Skip to main content

Table 1 General characteristics of the study population

From: Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP

Characteristic

Men (n = 373)

Women (n = 499)

p*

Age (years)

49 (38; 60)

49 (40; 59)

0.94

Smoking (%)

  

< 0.01

 Never smoker

32.7

49.7

 

 Former smoker

44.8

28.5

 

 Current smoker

25.5

21.8

 

Physically active (%)

74.3

73.7

0.93

Waist circumference (cm)

93 (85; 101)

80 (73; 89)

< 0.01

NT-probnp (ng/L)

32 (19; 55)

68 (41; 124)

< 0.01

Triglycerides (mmol/L)

1.27 (0.92; 1.88)

1.13 (0.81; 1.60)

< 0.01

HDL-cholesterol (mmol/L)

1.29 (1.11; 1.49)

1.58 (1.35; 1.83)

< 0.01

LDL-cholesterol (mmol/L)

3.35 (2.73; 3.96)

3.31 (2.72; 3.95)

0.55

Total cholesterol (mmol/L)

5.3 (4.5; 6.0)

5.5 (4.9; 6.2)

< 0.01

Egfr (mL/min/1.73 m2)

98 (89; 108)

98 (86; 107)

0.28

ALT (µkatal/L)

0.46 (0.35; 0.64)

0.30 (0.24; 0.41)

< 0.01

Ejection fraction (%)

72 (65; 77)

73 (68; 79)

< 0.01

Self-reported HF (%)

1.9%

2%

1.00

Adiponectin (ng/mL)

5644 (3814; 7782)

8851 (6333; 12,102)

< 0.01

  1. Continuous data are expressed as median (25th percentile; 75th percentile); nominal data are given as percentages. * χ2-test (nominal data) or Mann–Whitney-U test (interval data) were performed to compare men and women
  2. HDL high density lipoprotein, LDL low-density lipoprotein, NT-proBNP N-terminal prohormone of brain natriuretic peptide, eGFR estimated glomerular filtration rate, ALT alanine aminotransferase, HF heart failure